TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02290015

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: All treatments were performed by the same acupuncturist, who is a medical doctor with more than eight years of clinical and research experience in ACP for tinnitus. Acupoints described as being effective for tinnitus were selected according to TCM theory. Basic points that are manipulated in ACP include GV 20 (Baihui), TE 17 (Yifeng), GB 8 (Shuaigu), SI 19 (Tinggong), GB 2 (Tinghui), TE 21 (Ermen), VC 23 (Lianquan), GB 20 (Fengchi), TE 2 (Yemen), TE 5 (Waiguan), SI 2 (Qiangu), GB 43 (Xiaxi) and GB 41 (Zulinqi). However, several secondary (accessory) acupoints were also added according to TCM and the etiological diagnosis of tinnitus: GV 4 (Mingmen), KI 3 (Taixi), BL 23 (Shenshu), BL 19 (Danshu), BL 18 (Ganshu) and CV 4 (Guanyuan).
Study: NCT01114126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neu-P11
Description: comparison of different dosages of drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neu-P11
Description: comparison of different dosages of drug
Study: NCT02290015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: All treatments were performed by the same acupuncturist, who is a medical doctor with more than eight years of clinical and research experience in ACP for tinnitus. Acupoints described as being effective for tinnitus were selected according to TCM theory. Basic points that are manipulated in ACP include GV 20 (Baihui), TE 17 (Yifeng), GB 8 (Shuaigu), SI 19 (Tinggong), GB 2 (Tinghui), TE 21 (Ermen), VC 23 (Lianquan), GB 20 (Fengchi), TE 2 (Yemen), TE 5 (Waiguan), SI 2 (Qiangu), GB 43 (Xiaxi) and GB 41 (Zulinqi). However, several secondary (accessory) acupoints were also added according to TCM and the etiological diagnosis of tinnitus: GV 4 (Mingmen), KI 3 (Taixi), BL 23 (Shenshu), BL 19 (Danshu), BL 18 (Ganshu) and CV 4 (Guanyuan).
Study: NCT01114126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neu-P11
Description: comparison of different dosages of drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neu-P11
Description: comparison of different dosages of drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Neu-P11 placebo
Description: comparison of different dosages
Study: NCT03087448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: ALK tyrosine inhibitor, 300 mg - 450 mg PO daily.~Phase I dose escalation:~1. Ceritinib 300mg~2. Ceritinib 450mg~3. Ceritinib 450mg~The Phase II doses will be determined by Phase I dose escalation study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: MEK kinase inhibitor, 1.5 mg - 2.0 mg PO daily.~Phase I dose escalation:~1. Trametinib 1.5mg~2. Trametinib 1.5mg~3. Trametinib 2.0mg~The Phase II doses will be determined by Phase I dose escalation study
Study: NCT03581500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Carbon C 13 Pyruvate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Undergo MRSI
Study: NCT04918095

Intervention type: DEVICE
Intervention: CareCOPD Platform
Description: The subjects will be provided with CareCOPD devices for home monitoring of airway impedance, medication use, and symptoms data.
Study: NCT03742869

Intervention type: COMBINATION_PRODUCT
Intervention: A multi-omics analysis
Description: A multi-omics analysis including genome-wide association study, whole exome sequencing, transcriptomics and metabolomics.

Intervention type: COMBINATION_PRODUCT
Intervention: A multi-omics analysis
Description: A multi-omics analysis including genome-wide association study, whole exome sequencing, transcriptomics and metabolomics.
Study: NCT04106609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised, individualized exercise oncology program
Description: The study intervention is a supervised, individualized exercise oncology program described in previous literature2,3,12 and provided by Maple Tree Cancer Alliance, a non-profit organization providing exercise training to individuals with cancer (https://www.mapletreecanceralliance.org/). This organization was founded in 2011 and currently operates in 9 hospitals serving Ohio and Pennsylvania, offering free exercise programs and nutritional guidance to approximately 500 patients annually to help relieve side effects related to cancer treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current standard of care
Description: Resource guide with various options available to cancer survivor. Within this guide are tips for healthy eating and pictures of standard exercises to improve fitness.
Study: NCT00370929

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Study: NCT03962426

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SocialVille Social Cognitive Training
Description: SocialVille exercises in this study include 4 exercises:~* Recognition: a speeded face matching task~* Face to Face: a speeded facial emotion matching task~* Gaze Match: a speeded gaze matching task~* Face Poke: a continuous performance task with facial expressions
Study: NCT01515423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (20% Intralipid)
Description: Form= injection, route= intramuscular use. One injection monthly when not receiving active medication for 48 weeks.
Study: NCT03192631

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial incentive
Description: Incentive of $15 Canadian
Study: NCT01123616

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: abdominal wall closure
Description: triclosan-coated (PDS-Plus) and non-coated (PDS) suture to close the abd. wall

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: abdominal wall closure
Description: triclosan-coated (PDS-Plus) and non-coated (PDS) suture to close the abd. wall
Study: NCT02784171

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Study: NCT03842033

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PEAKmAAP
Description: The PEAKmAAP group will use a mobile app that will help manage asthma.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PEAKmAAP-DS
Description: This group will use the mobile app to help manage asthma. the primary care provider will receive monthly reports to help him/her know how the participants asthma symptoms are over time.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: NutriMap Usual Care
Description: This group will use a non-asthma related app daily to record their daily intake of fruits and vegetables.
Study: NCT03805789

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alpha-1 antitrypsin (AAT)
Description: Alpha-1 antitrypsin is a lyophilized product for intravenous administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alpha-1 antitrypsin (AAT)
Description: Alpha-1 antitrypsin is a lyophilized product for intravenous administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alpha-1 antitrypsin (AAT)
Description: Alpha-1 antitrypsin is a lyophilized product for intravenous administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alpha-1 antitrypsin (AAT)
Description: Alpha-1 antitrypsin is a lyophilized product for intravenous administration.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Albumin solution administered intravenously
Study: NCT02595424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT04307485

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: 90mg ticargrelor based DAPT vs 60mg ticargrelor based DAPT
Study: NCT02505633

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stimuplex insulated needle
Description: 2P2I group: nerve stimulating needle is advanced twice and LA is injected 15 mL at a time.~1P1I group: nerve stimulating needle is advanced once and LA is injected 30 mL.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimuplex insulated needle
Description: 2P2I group: nerve stimulating needle is advanced twice and LA is injected 15 mL at a time.~1P1I group: nerve stimulating needle is advanced once and LA is injected 30 mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine mixed with epinephrine
Description: 2P2I group and 1P1I group use the same LA (1.5% lidocaine mixed with 1:200,000 epinephrine). But 2P2I group is injected LA at equally divided doses (15 mL at a time). 1P1I group is injected LA 30 mL at once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine mixed with epinephrine
Description: 2P2I group and 1P1I group use the same LA (1.5% lidocaine mixed with 1:200,000 epinephrine). But 2P2I group is injected LA at equally divided doses (15 mL at a time). 1P1I group is injected LA 30 mL at once.
Study: NCT03867513

Intervention type: OTHER
Intervention: Multimodal imaging
Description: All participants will attend the Sir Peter Mansfield Imaging Centre for a scanning session using three imaging systems (SQUID MEG, OPM MEG and 7T MRI), cognitive testing and symptom questionnaires. Remote symptom monitoring and cognitive testing at three and six months.

Intervention type: OTHER
Intervention: Multimodal imaging
Description: All participants will attend the Sir Peter Mansfield Imaging Centre for a scanning session using three imaging systems (SQUID MEG, OPM MEG and 7T MRI), cognitive testing and symptom questionnaires. Remote symptom monitoring and cognitive testing at three and six months.
Study: NCT00358462

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: two 500mg tablets or four 250mg tablets administered as a single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: one 100mg capsule administered twice daily for seven days
Study: NCT03482388

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crowdsourced materials
Description: Among participants randomized to the intervention arm, intervention images and videos promoting HBV and HCV testing will be delivered through the WeChat platform. Men will also be invited to submit suggestions for how to improve intervention videos and images.
Study: NCT00006890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Prednisone 50mg on alternate days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: THALIDOMIDE 200 mg qhs
Study: NCT01983657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhGM-CSF
Description: GM-CSF will be given subcutaneously according to the rule in different groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhGM-CSF
Description: GM-CSF will be given subcutaneously according to the rule in different groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhGM-CSF
Description: GM-CSF will be given subcutaneously according to the rule in different groups.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhGM-CSF
Description: GM-CSF will be given subcutaneously according to the rule in different groups.
Study: NCT03482388

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Participants will not view any images or videos promoting HBV and HCV testing.
Study: NCT02416505

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Verbal+Anatomic Model
Study: NCT01983657

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Whole Lung Lavage(WLL)
Description: using double lumen endotracheal tube (DLT) to selectively lavage one lung
Study: NCT03979443

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Discharge on the day of surgery
Description: Patient discharge on the day of the surgery, usually within 6-8 hours after procedure
Study: NCT01515423

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PP1M 50 mg eq.
Description: Type= exact number, unit= mg eq., number= 50, form= injection, route= intramuscular use. One injection every month for 48 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PP1M 75 mg eq.
Description: Type= exact number, unit= mg eq., number= 75, form= injection, route= intramuscular use. One injection every month for 48 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PP1M 100 mg eq.
Description: Type= exact number, unit= mg eq., number= 100, form= injection, route= intramuscular use. One injection every month for 48 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PP1M 150 mg eq.
Description: Type= exact number, unit= mg eq., number= 150, form= injection, route= intramuscular use. One injection every month for 48 weeks.
Study: NCT02312167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: confocal laser endomicroscopy
Description: probe-based and needle-based confocal laser endomicroscopy
Study: NCT01598961

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TOF count-guided partial NMB
Description: Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: T1/Tc guided partial NMB
Description: Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No NMB
Description: to maintain no neuromuscular blockade during LSR monitoring except the intubation dose during anesthetic induction
Study: NCT02968576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TENOFOVIR DISOPROXIL FUMARATE 300 Mg / EMTRICITABINE 200 Mg ORAL TABLET [TRUVADA]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TENOFOVIR DISOPROXIL FUMARATE 300 Mg / EMTRICITABINE 200 Mg ORAL TABLET [TRUVADA]

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proteus Sensor System
Study: NCT00685152

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS) (MagPro, Medtronic)
Description: 6 weeks of either Active or Sham Repetitive Transcranial Magnetic Stimulation (rTMS). Active treatment comprises of stimulation with rTMS frequency 20Hz, intensity 110% of Motor Threshold, 20 trains, 9 seconds per train, 51 seconds of intertrain interval that is applied over the Right Dorsolateral Prefrontal Cortex by a figure eight shaped coil. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6. Sham treatment will mimic active treatment; The rTMS machine used is MagPro and the company name is Medtronic.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS) (MagPro, Medtronic)
Description: 6 weeks of either Active or Sham Repetitive Transcranial Magnetic Stimulation (rTMS). Active treatment comprises of stimulation with rTMS frequency 20Hz, intensity 110% of Motor Threshold, 20 trains, 9 seconds per train, 51 seconds of intertrain interval that is applied over the Right Dorsolateral Prefrontal Cortex by a figure eight shaped coil. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6. Sham treatment will mimic active treatment; The rTMS machine used is MagPro and the company name is Medtronic.
Study: NCT01633697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pranayama
Description: Specific yoga-related breathing method.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Education alone
Description: No special attention to breathing
Study: NCT03522376

Intervention type: OTHER
Intervention: Loaded inspiratory muscle test
Description: Loaded inspiratory muscle tests will be set at 30% and 50% of maximal inspiratory pressure. The orders of the two loaded test conditions will be conducted in random order with at least 24 hours separation. This is an observational study. Subjects will perform only 15 breaths with each loaded test condition to exam the performance of their inspiratory muscles. Loaded inspiratory muscle test is not for training.
Study: NCT02842502

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collection of supernumerary biopsies during skin graft pellet procedure
Study: NCT00855140

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture, derived from the TCM literature, specific for insomnia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture, derived from the TCM literature, specific for insomnia
Study: NCT06726603

Intervention type: PROCEDURE
Intervention: Assisted Reproductive Technology
Description: Assisted Reproductive Technology for the purposes of this study include IVF and IVF+ICSI. Ovulation induction methods are not considered Assisted Reproductive Technology
Study: NCT02416505

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Verbal+Video
Study: NCT04662424

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music in labor
Description: Women in the intervention group will be offered music in labor, defined listening to music from the randomization until the delivery of the baby. Women had the possibility to select the songs at their discretion
Study: NCT00690534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Regular
Description: insulin, 0.2 mU/kg/min for 3 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Regular
Description: insulin, 0.2 mU/kg/min for 3 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Regular
Description: insulin, 0.2 mU/kg/min for 3 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Regular
Description: insulin, 0.2 mU/kg/min for 3 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NMMA
Description: variable rate for 3 hours
Study: NCT01898390

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transplant
Description: Bilateral Neural Allo-Transplantation with Fetal Ventral Mesencephalic Tissue
Study: NCT02736006

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20 meters air dive
Description: A dive in the depth of 20 m during 40 minutes. The divers will be evaluated before and 30, 60, 180 minutes after a 20 meters air dive. Venous bubbles will be detected by precordial Doppler 30 minutes after the dive.~In association with this Doppler, Flow Mediated Dilation, blood samples analysing inflammatory and thrombotic factors and other biomarkers will be explored before and after the dive in order to know how vascular and respiratory tracts in this environment react.
Study: NCT00919607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine fumarate extended-release
Description: 200mg,oral,single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quetiapine fumarate extended-release
Description: 300mg,oral,single dose
Study: NCT00361556

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Back Book
Description: A book on how to prevent back pain

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Back Guide
Description: A guide for the prevention of back pain.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Back Guide
Description: A guide for the prevention of back pain.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General health book
Description: A book on general health

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General health book
Description: A book on general health

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General health book
Description: A book on general health
Study: NCT03374033

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NUTR +
Description: one extra g/kg/d of protein and lipids starting before 48 hours after birth until 36 weeks postmenstrual age

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NUTR +
Description: one extra g/kg/d of protein and lipids starting before 48 hours after birth until 36 weeks postmenstrual age

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STIMUL +
Description: Physical activity stimulation consists in flexion/extension of the 4 limbs and other motion exercises of the shoulder girdle and of the hips. This stimulation will take place before the feed for a mean of 30 times a week (minimum 24- maximum 36 times a week, 10 minutes each time) and will start within the 10th day of life until 36 weeks postmenstrual age

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STIMUL +
Description: Physical activity stimulation consists in flexion/extension of the 4 limbs and other motion exercises of the shoulder girdle and of the hips. This stimulation will take place before the feed for a mean of 30 times a week (minimum 24- maximum 36 times a week, 10 minutes each time) and will start within the 10th day of life until 36 weeks postmenstrual age